Product Information
Registration Status: ActiveSIN11543P
PAMISOL CONCENTRATED INJECTION 30mg/10ml is approved to be sold in Singapore with effective from 2001-06-06. It is marketed by HOSPIRA SINGAPORE PTE LTD, with the registration number of SIN11543P.
This product contains Pamidronic Acid 3mg in the form of INJECTION. It is approved for INTRAVENOUS use.
This product is manufactured by Hospira Australia Pty Ltd in AUSTRALIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate.
Indication
For the treatment of moderate or severe hypercalcemia associated with malignancy
Mechanism of Action
The mechanism of action of pamidronate is inhibition of bone resorption. Pamidronate adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. Pamidronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Pharmacokinetics
- Absorption
- Plasma concentration rises rapidly upon IV administration.
- Distribution
- Metabolism
- Pamidronate is not metabolized and is exclusively eliminated by renal excretion
- Elimination
Clearance
* 107 +/- 50 mlL/min
Toxicity
Side effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood
Active Ingredient/Synonyms
Acide pamidronique | Acido pamidronico | Acidum pamidronicum | Pamidronic acid | Ribodroat | Pamidronate |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.